PlatoScience (PlatoWork / PlatoCare)
Clinician-supervised remote tDCS platform — patient uses at home but protocols are prescribed/monitored by a healthcare provider
CE MARK · EU CE-MDR
EU CE-MDR certified. Meets European medical device safety requirements.
Key facts at a glance.
- Founded
- 2015
- Headquarters
- Copenhagen, Denmark
What the device does.
- + Wireless, fully remote configuration via clinician dashboard
- + Plug-and-play with pre-built protocols
- + No expensive consumables
- + PlatoCare (MDR Class IIa) for depression treatment
- + PlatoWork (CE-marked) generic tDCS
- + Remote session monitoring and compliance tracking
- + ISO 13485 certified manufacturing
The trade-offs.
- + **Clinician-supervised remote tDCS platform** — patient at home, protocols prescribed/monitored by healthcare provider
- + CE-marked European regulatory positioning
- + 2015-founded Copenhagen Denmark with established clinical-channel adoption
- + Bridges DTC consumer + clinical-prescribed pathway
- + Multiple product line (PlatoWork productivity / PlatoCare clinical)
- − Not FDA-cleared for US market (CE-marked European-only)
- − Clinician requirement adds friction vs DTC alternatives
- − Limited US distribution
- − Smaller brand awareness vs Caputron / Flow Neuroscience in US
Clinical practitioners, academic researchers, supervised at-home patients (primarily EU/UK)
The long read.
§ Hands-on instrument testing pending. Based on published specifications and third-party data.
Overview
PlatoScience (PlatoWork / PlatoCare) is the clinician-supervised remote tDCS platform specialist — founded 2015 in Copenhagen Denmark, with structural value claim built on clinician-supervised remote tDCS platform — patient uses at home but protocols are prescribed/monitored by healthcare provider + CE-marked European regulatory positioning + dual product line (PlatoWork productivity / PlatoCare clinical). For users wanting clinician-prescribed tDCS pathway in EU markets, PlatoScience is structurally distinctive.
The structural editorial caveats: not FDA-cleared for US market (CE-marked European-only), clinician requirement adds friction vs DTC alternatives, limited US distribution, and smaller brand awareness vs Caputron / Flow Neuroscience in US market.
When PlatoScience Makes Sense
Strong fit: EU buyers wanting clinician-supervised tDCS; productivity + clinical dual-product line use cases; bridge between DTC + clinical-prescribed pathway; CE-marked regulatory positioning preference.
Weaker fit: US-buyers wanting FDA-cleared positioning (Flow Neuroscience FL-100 PMA); DTC consumer-direct (TheBrainDriver, LIFTiD); off-label FDA-cleared chassis (Caputron); EU prescribed depression specialist (Sooma).
3-Year Cost of Ownership
Pricing varies by clinician-prescribed protocol pathway. EU-only currently.
Verdict: Recommended
PlatoScience (PlatoWork / PlatoCare) earns a recommended verdict on clinician-supervised remote tDCS platform positioning, CE-marked European regulatory positioning, 2015-founded Copenhagen-established clinical-channel adoption, dual-product-line PlatoWork productivity / PlatoCare clinical, and bridge between DTC consumer + clinical-prescribed pathway — balanced against not-FDA-cleared for US market, clinician requirement friction, limited US distribution, and smaller US brand awareness.
For EU buyers wanting clinician-supervised tDCS productivity + clinical use cases, structurally distinctive. For US FDA-cleared positioning, DTC consumer-direct, or US-domestic alternatives, better matches exist.
Changelog
- 2026-05-07: Initial review published based on PlatoScience published specifications.
What we'll measure on the bench.
- Protocol
- Multimeter at electrodes (current source verification)
- Primary metric
- Output current at each preset (mA)
- Pass threshold
- within ±10% of selected current
- Session shape
- 3 measurements per preset × all presets
§ Bench session pending. Measured values will replace this panel as the protocol completes — see Plate VI · Methodology for the full testing rulebook.